Raphael Rousseau

Executive Officer at Pheast Therapeutics.

Raised on Pheast Therapeutics filings

$99.8M

of $115.2M offered across 2 Form D filings

Form D filings: 2
Teammates: 6
Last filing: Oct 16, 2025

Company

Pheast Therapeutics

Biotech · Redwood City, CA

Antibody that blocks CD24 so macrophages attack cancer

Antibody that blocks CD24 so macrophages attack cancer

Investors: 7
Founded: 2020
Still open: $15.4M

Investors: 7
Sector: Biotech
Founded: 2020
HQ: Redwood City, CA

Pheast Therapeutics filings

Pheast Therapeutics Form D filings
Filed	Security	Sold of offered	Filing
Oct 16, 2025	Equity	$24.6M/ $40M	Form D
Apr 10, 2025	Equity	$75.3M/ $75.3M	Form D/A

EquityFiled Oct 16, 2025Form D
$24.6M/ $40M
EquityFiled Apr 10, 2025Form D/A
$75.3M/ $75.3M

Works with

Also named on Pheast Therapeutics filings

Roy MauteChief Executive Officer, Form D signerForm D signer Amira BarkalDirector Irving WeissmanDirector Jacob VogelsteinDirector Steven GillisDirector Thomas MartyExecutive Officer